WeChat Mini Program
Old Version Features

Abstract OT3-05-01: Adaptive Multi-Drug Treatment of Evolving Cancers (AMTEC): A Phase II, Open-Label, Study of Olaparib in Combination with Either Durvalumab, Selumetinib or Capivasertib, or Ceralasertib Monotherapy in Patients with Metastatic TNBC

Evthokia Hobbs,Gordon Mills,Jeong Lim,Marlana Klinger,Kiara Siex,Sidney Huszti, Annie Yang,Danielle Galipeau,Christina Zheng,Lauren Murray,Becky Goodford,Nicholas Marter-Sanders,Anastasiya Olson,Jayne Stommel,Brett Johnson,Jamie Keck,Ben Kong,Allison Solanki,Shaun Goodyear,Christopher Corless,Joe Gray,Mitri Zahi

CANCER RESEARCH（2023）

Cited 0|Views30
Key words
Cancer Therapy,PARP Inhibitors,Olaparib
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined